These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 16555432

  • 1. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
    Badros A, Gahres N.
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z.
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib in multiple myeloma.
    Vandenbroucke JP, Kroep JR.
    N Engl J Med; 2005 Sep 22; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
    [No Abstract] [Full Text] [Related]

  • 5. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V, Palumbo A.
    Cancer J; 2009 Sep 22; 15(6):494-501. PubMed ID: 20010169
    [Abstract] [Full Text] [Related]

  • 6. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
    Prince HM, Schenkel B, Mileshkin L.
    Leukemia; 2007 Apr 22; 21(4):818-20; author reply 821. PubMed ID: 17301817
    [No Abstract] [Full Text] [Related]

  • 7. New developments in the treatment of patients with multiple myeloma.
    Minnema MC, van der Spek E, van de Donk NW, Lokhorst HM.
    Neth J Med; 2010 Jan 22; 68(1):24-32. PubMed ID: 20103818
    [Abstract] [Full Text] [Related]

  • 8. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M, Noborio-Hatano K, Takahashi S, Kikuchi S, Mori M, Muroi K, Komatsu N, Ozawa K.
    Rinsho Ketsueki; 2004 Feb 22; 45(2):144-8. PubMed ID: 15045823
    [Abstract] [Full Text] [Related]

  • 9. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.
    Expert Rev Hematol; 2011 Feb 22; 4(1):51-60. PubMed ID: 21322778
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P, Gruppo Italiano Trapianti di Midollo.
    Haematologica; 2006 Jun 22; 91(6):837-9. PubMed ID: 16769588
    [Abstract] [Full Text] [Related]

  • 11. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK, Richards TA, Weber DM.
    Cancer J; 2009 Jun 22; 15(6):485-93. PubMed ID: 20010168
    [Abstract] [Full Text] [Related]

  • 12. New drugs for myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.
    Oncologist; 2007 Jun 22; 12(6):664-89. PubMed ID: 17602058
    [Abstract] [Full Text] [Related]

  • 13. Proteasome inhibition in multiple myeloma.
    Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.
    Eur J Cancer; 2006 Jul 22; 42(11):1623-39. PubMed ID: 16820291
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
    Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC.
    Br J Haematol; 2008 Nov 22; 143(4):511-9. PubMed ID: 18986387
    [Abstract] [Full Text] [Related]

  • 15. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.
    Cancer; 2007 Sep 01; 110(5):1042-9. PubMed ID: 17654660
    [Abstract] [Full Text] [Related]

  • 16. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P.
    Semin Hematol; 2005 Oct 01; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [Abstract] [Full Text] [Related]

  • 17. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M, Oguro R, Yamanaka C, Takada K, Matsuura Y, Akiba T, Aotsuka N, Tani Y, Wakita H.
    J Pharm Pharm Sci; 2011 Oct 01; 14(1):78-89. PubMed ID: 21501555
    [Abstract] [Full Text] [Related]

  • 18. Clinical management of myeloma--state of the art.
    Harousseau JL.
    Cancer Treat Rev; 2010 May 01; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib in multiple myeloma.
    Cecchi M, Caccese E, Messori A.
    N Engl J Med; 2005 Sep 22; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
    [No Abstract] [Full Text] [Related]

  • 20. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL.
    Br J Haematol; 2008 Oct 22; 143(2):222-9. PubMed ID: 18713253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.